SCHEMBL5537549

SCHEMBL5537549

CCNC1CCN(c2ccc([O])cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
ME3 Q16798 1/20 0.40
USP2 O75604 1/20 0.38
NPY2R P49146 1/20 0.38
GAA P10253 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
RAD52 P43351 1/20 0.38
GFER P55789 1/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
EPHX2 P34913 1/20 0.37
L3MBTL3 Q96JM7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
AKT1 P31749 1/20 0.36
USP28 Q96RU2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540075 0.87 SMN1; SMN2 (0.40) SMN1; SMN2ME3USP2NPY2RGAA
SCHEMBL13380458 0.85 MAPT (0.54) SMN1; SMN2HSP90AA1HSP90AB1ME3USP2
SCHEMBL8725147 0.85 ADRB1 (0.46) SMN1; SMN2HSP90AA1HSP90AB1GAAKDM4E
SCHEMBL8725144 0.83 HSP90AA1 (0.40) SMN1; SMN2HSP90AA1HSP90AB1ME3USP2
SCHEMBL5537556 0.83 ME3 (0.52) SMN1; SMN2HSP90AA1HSP90AB1ME3USP2
SCHEMBL22837858 0.83 HSP90AA1 (0.40) SMN1; SMN2HSP90AA1HSP90AB1ME3USP2
SCHEMBL13798544 0.83 CHRNA7 (0.50) SMN1; SMN2HSP90AA1HSP90AB1ME3NPY2R
SCHEMBL13785108 0.83 SMN1; SMN2 (0.40) SMN1; SMN2HSP90AA1HSP90AB1ME3USP2
SCHEMBL5535481 0.81 HSP90AA1 (0.41) SMN1; SMN2HSP90AA1HSP90AB1ME3NPY2R
SCHEMBL5537144 0.81 MCHR1 (0.42) SMN1; SMN2ME3USP2GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SMN1; SMN2 3985/4885HSP90AA1 2426/4885HSP90AB1 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.